Home > Insider Trading > Filing (0001209191-16-155989)

Filing Details

Accession Number:: 0001209191-16-155989
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-12-19 17:50:43
Reporting Period:: 2016-12-15

Filing Date:: 2016-12-19
Accepted Time:: 2016-12-19 17:50:43
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1567514	Intra-Cellular Therapies Inc.	ITCI	Pharmaceutical Preparations (2834)	364742850

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1585669	E. Kimberly Vanover	C/O Intra-Cellular Therapies, Inc. 430 East 29Th Street New York NY 10016	Svp, Clinical Development	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2016-12-15	5,000	$1.36	5,000	No	4	M	Direct
Common Stock	Disposition	2016-12-15	2,500	$15.26	2,500	No	4	S	Direct
Common Stock	Acquisiton	2016-12-15	10,000	$1.50	12,500	No	4	M	Direct
Common Stock	Disposition	2016-12-15	5,000	$15.19	7,500	No	4	S	Direct
Common Stock	Acquisiton	2016-12-15	3,750	$1.50	11,250	No	4	M	Direct
Common Stock	Disposition	2016-12-15	1,875	$15.28	9,375	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2016-12-15	5,000	$0.00	5,000	$1.36
Common Stock	Stock Option (right to buy)	Disposition	2016-12-15	10,000	$0.00	10,000	$1.50
Common Stock	Stock Option (right to buy)	Disposition	2016-12-15	3,750	$0.00	3,750	$1.50

Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
2017-04-11	No	4	M	Direct
2017-12-12	No	4	M	Direct
2018-12-18	No	4	M	Direct

Footnotes

All exercises of options and sales of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2016.
This Form 4 reports the exercise of an option to purchase 5,000 shares of the Issuer's common stock that was to expire on April 11, 2017, and a sale of an aggregate of 2,500 of such shares primarily to cover the reporting person's tax liability.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.09 to $15.39, inclusive. The reporting person undertakes to provide Intra-Cellular Therapies, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (5) and (7) to this Form 4.
This Form 4 reports the exercise of an option to purchase 10,000 shares of the Issuer's common stock that was to expire on December 12, 2017, and a sale of an aggregate of 5,000 of such shares primarily to cover the reporting person's tax liability.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.09 to $15.39, inclusive.
This Form 4 reports the exercise of an option to purchase 3,750 shares of the Issuer's common stock that was to expire on December 18, 2018, and a sale of an aggregate of 1,875 of such shares primarily to cover the reporting person's tax liability.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.12 to $15.39, inclusive.
All shares underlying this option have vested.